Pichiorri Lead Clinical Trials

The following is a select list of high-impact clinical trials being conducted by City of Hope's multiple myeloma team, where Dr. Pichiorri serves as a scientific lead:

Radioimmunotherapy

• *IRB# 21599 – Phase 1 Trial of 225Actinium-DOTA-Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma 

Drug repurposing

• *IRB# 19418 - A Phase 2 Trial of leflunomide, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma 
• *IRB# 21049 – Phase 2 Trial of Leflunomide in African American and European American patients with high-risk Smoldering multiple myeloma

Maintenance approaches

• *IRB# 18560 - A Multicenter, Open-label, Single Arm, Phase II study of Daratumumab as Consolidation/Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma) 

Amyloidosis

• *IRB# 21395 – A Phase 1/1a Study of Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis.

Oncolytic viruses

• NCT03605719 – Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma - View - ClinicalTrials.gov

*This trial is sponsored by City of Hope. For further information about City of Hope trials, please visit City of Hope.